Get the Stockscreener App
14.39
2.64%
0.37
Zymeworks Inc. stock is traded at $14.39, with a volume of 339.00K.
It is up +2.64% in the last 24 hours and up +0.70% over the past month.
Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company's lead product candidate is ZW25, a novel bispecific antibody that is in Phase I clinical trial for the treatment of breast and gastric cancer. It is also developing ZW49, a bispecific antibody-drug conjugate that is in IND application stage. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Celgene Corporation and Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; and Janssen Biotech, Inc., as well as a collaboration agreement with Celgene Corporation. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies targeting cytokine-receptor pathways. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.
See More
Previous Close:
$14.02
Open:
$14.19
24h Volume:
339.00K
Relative Volume:
0.79
Market Cap:
$991.15M
Revenue:
$62.71M
Net Income/Loss:
$-112.51M
P/E Ratio:
-9.5298
EPS:
-1.51
Net Cash Flow:
$-96.01M
1W Performance:
-4.13%
1M Performance:
+0.70%
6M Performance:
+29.64%
1Y Performance:
+22.57%
1-Day Range:
$13.85
$14.40
1-Week Range:
$13.85
$15.25
52-Week Range:
$7.97
$17.70
Zymeworks Inc. Stock (ZYME) Company Profile
Name
Zymeworks Inc.
Sector
Industry
Phone
604-678-1388
Address
1385 West 8th Avenue, Suite 540, Vancouver, BC
Compare ZYME with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZYME
Zymeworks Inc.
|
14.39 | 991.15M | 62.71M | -112.51M | -96.01M | -1.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-16-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-07-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-01-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Mar-21-23 | Resumed | Wells Fargo | Overweight |
| Jan-04-23 | Reiterated | H.C. Wainwright | Neutral |
| Dec-20-22 | Upgrade | Jefferies | Hold → Buy |
| Nov-01-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-21-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-04-22 | Resumed | Wells Fargo | Overweight |
| May-05-22 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-15-22 | Initiated | Evercore ISI | Outperform |
| Dec-10-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Nov-17-21 | Resumed | Guggenheim | Neutral |
| Oct-07-21 | Initiated | Jefferies | Hold |
| Mar-31-21 | Initiated | Credit Suisse | Outperform |
| Feb-25-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-08-21 | Resumed | H.C. Wainwright | Buy |
| Jan-25-21 | Downgrade | Citigroup | Buy → Neutral |
| Sep-29-20 | Resumed | JP Morgan | Neutral |
| Aug-06-20 | Initiated | SVB Leerink | Outperform |
| Jan-10-20 | Initiated | Wolfe Research | Outperform |
| Dec-09-19 | Initiated | JP Morgan | Neutral |
| Nov-25-19 | Initiated | H.C. Wainwright | Buy |
| Nov-20-19 | Initiated | Guggenheim | Buy |
| Sep-30-19 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-30-19 | Initiated | Stifel | Buy |
| Jul-18-19 | Initiated | Deutsche Bank | Buy |
| May-11-18 | Upgrade | Barclays | Underweight → Equal Weight |
| Mar-19-18 | Initiated | Raymond James | Outperform |
View All
Zymeworks Inc. Stock (ZYME) Latest News
Zymeworks Inc. (NYSE:ZYME) Receives $19.17 Average Price Target from Brokerages - MarketBeat
Brokerages Set Zymeworks Inc. (NYSE:ZYME) Target Price at $19.17 - Defense World
Zymeworks Inc. Announces Appointment of Oleg Nodelman to the Board of Directors - Marketscreener.com
Zymeworks Welcomes Oleg Nodelman to Board of Directors - TipRanks
Zymeworks Announces Appointment Of Oleg Nodelman To Board Of Directors -February 18, 2025 at 06:18 am EST - Marketscreener.com
Zymeworks Inc. Appoints Oleg Nodelman to Board of Directors as Part of Ongoing Board Renewal Process - Nasdaq
Zymeworks Announces Appointment of Oleg Nodelman to Board of Directors - GlobeNewswire
Major Strategic Move: Zymeworks Adds Largest Shareholder's Founder to Board, Signaling Growth Focus - StockTitan
Zymeworks BC Inc (ZYME) can make a big difference with a little luck - SETE News
Zymeworks (NYSE:ZYME) Stock Price Down 5.4%Should You Sell? - MarketBeat
Q1 Earnings Forecast for Zymeworks Issued By Leerink Partnrs - MarketBeat
Zymeworks to Announce 2024 Financial Results and Host Corporate Update - TipRanks
Zymeworks To Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 5, 2025 - The Korea Bizwire
Zymeworks Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 5, 2025 - Nasdaq
Earnings Alert: Zymeworks Schedules Critical Year-End ResultsKey Details Inside - StockTitan
Zymeworks (NYSE:ZYME) Trading Down 5.4% – What’s Next? - Defense World
Zymeworks: Its Post-Approval Future (NASDAQ:ZYME) - Seeking Alpha
Recent Insider Activity Could Benefit Zymeworks BC Inc (ZYME) - Knox Daily
You might want to take a look at Zymeworks BC Inc (ZYME) now - SETE News
SG Americas Securities LLC Has $392,000 Position in Zymeworks Inc. (NYSE:ZYME) - Defense World
Zymeworks to Engage Investors at Key Conferences - TipRanks
Zymeworks Announces Participation in Upcoming Investor Conferences - The Manila Times
Cancer Drug Developer Zymeworks Takes Center Stage at Oppenheimer, Citi, and B. Riley Events - StockTitan
Zymeworks (NASDAQ:ZYME) shareholder returns have been respectable, earning 79% in 3 years - Simply Wall St
The past five years for Zymeworks (NASDAQ:ZYME) investors has not been profitable - Yahoo Finance
Zymeworks Inc. (NYSE:ZYME) Director Ecor1 Capital, Llc Buys 19,748 Shares - MarketBeat
Zymeworks Inc. (NYSE:ZYME) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Analysts Set Zymeworks Inc. (NYSE:ZYME) PT at $19.17 - MarketBeat
EcoR1 Capital, LLC Expands Stake in Zymeworks Inc with Strategic Acquisition - GuruFocus.com
Assenagon Asset Management S.A. Raises Position in Zymeworks Inc. (NYSE:ZYME) - Defense World
Assenagon Asset Management S.A. Boosts Stake in Zymeworks Inc. (NYSE:ZYME) - MarketBeat
Engineered Multispecific Antibodies Innovation Research Report 2024: Patent Trends Show a Noticeable Surge in 2023 with Regeneron, Roche, and Amgen Emerging as the Top Patent Filers - GlobeNewswire Inc.
Zymeworks (NYSE:ZYME) Shares Gap Up Following Insider Buying Activity - Defense World
Opinion: Four trends to watch in B.C.'s tech sector - Business in Vancouver
Zymeworks (NYSE:ZYME) Shares Gap Up on Insider Buying Activity - MarketBeat
EcoR1 Capital, LLC Increases Stake in Zymeworks Inc - GuruFocus.com
ZYME (Zymeworks) Total Stockholders Equity : $366.98 Mil (As of Sep. 2024) - GuruFocus.com
Insider Buying: Zymeworks Inc. (NYSE:ZYME) Director Acquires 74,125 Shares of Stock - MarketBeat
Ecor1 capital acquires $2.28 million in Zymeworks stock By Investing.com - Investing.com Nigeria
Ecor1 Capital, Llc Buys 39,029 Shares of Zymeworks Inc. (NYSE:ZYME) Stock - MarketBeat
Ecor1 capital acquires $2.28 million in Zymeworks stock - Investing.com
Zymeworks Inc. (NYSE:ZYME) Director Ecor1 Capital, Llc Acquires 204,098 Shares of Stock - MarketBeat
Ecor1 Capital, Llc Purchases 21,021 Shares of Zymeworks Inc. (NYSE:ZYME) Stock - MarketBeat
Ecor1 capital increases stake in Zymeworks with $2.97 million purchase By Investing.com - Investing.com South Africa
Zymeworks Inc. Stock (ZYME) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):